ONTXEarnings•prnewswire•
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Sentiment:Neutral (60)
Summary
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 8, 2025 by prnewswire